Genomic drug developer Tessera Therapeutics raised $230m in a round co-led by SoftBank Vision Fund 2 as it works on its gene writing technology.
Telecommunications and internet conglomerate SoftBank’s Vision Fund 2 co-led a series B round for US-based genomic drug developer Tessera Therapeutics yesterday sized at more than $230m.
The round was co-led by the state-owned Alaska Permanent Fund Corporation and venture capital firm Altitude Life Science Ventures, and it also featured sovereign wealth fund Qatar Investment Authority and undisclosed other investors.
Tessera is developing therapeutics for genetic diseases that will utilise gene writing, a technique that involves writing therapeutic messages into the…
